Rufloxacin Hydrochloride Capsules

This product has a broad-spectrum antibacterial effect and has a good antibacterial effect on Gram-negative bacteria, including Escherichia coli, Salmonella typhi, Shigella, Haemophilus influenzae, Neisseria gonorrhoeae, etc. It also has a certain antibacterial effect on Gram-positive cocci such as Staphylococcus and hemolytic Streptococcus. It is ineffective against Pseudomonas aeruginosa. This product is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibits DNA synthesis and replication, and causes bacterial death. Literature reports that it has strong antibacterial activity in vivo and has an immunomodulatory effect.

The main ingredient of this product is rufloxacin hydrochloride.

This product is a capsule, and the contents are yellow powder.

Used for lower respiratory tract and urogenital system infections caused by sensitive bacteria.

Oral administration: 0.2g (equivalent to 2 tablets) once a day. Double the first dose to 0.4g (equivalent to 4 tablets). The course of treatment is 5 to 10 days. The course of treatment for prostatitis can be up to 4 weeks.

1. Gastrointestinal reactions are relatively common and may manifest as abdominal discomfort or pain, diarrhea, nausea or vomiting. 2. Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3. Allergic reactions: rash, skin itching, and occasionally exudative erythema multiforme and angioneurotic edema. In severe cases, tongue swelling, vocal cord edema, dyspnea, shock, etc. may be seen. A small number of patients have photosensitivity reactions. 4. Occasionally, (1) epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, and tremors may occur. (2) Manifestations of interstitial nephritis such as hematuria, fever, and rash. (3) Phlebitis. (4) Crystalluria, which is more common when used in high doses. (5) Joint pain. 5. A small number of patients may experience elevated serum aminotransferases, elevated blood urea nitrogen, and decreased peripheral white blood cell counts.

1. Patients who are allergic to this product and fluoroquinolones are contraindicated. 2. Like other quinolones, this product should not be used in patients with epilepsy or a history of convulsions. 3. As the safety of this product in the following aspects has not been fully determined and the possibility of damaging developing joint cartilage cannot be ruled out, this product is not suitable for pregnant or lactating women and children or young patients whose bones have not yet fully developed.

Precautions for children: The safety of this product for infants and adolescents under 18 years of age has not been determined. However, this product can cause joint lesions when used in several young animals. Therefore, it should not be used in children and adolescents under 18 years of age. Precautions for pregnancy and lactation: Animal experiments have not confirmed that quinolones are teratogenic, but studies on the use of drugs in pregnant women have not yet reached a clear conclusion. Since this drug can cause joint lesions in underage animals, it is contraindicated for pregnant women, and breastfeeding should be suspended when used by lactating women. Precautions for the elderly: Elderly patients often have impaired renal function, and since this product is partially excreted through the kidneys, it needs to be used in reduced doses.

1. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the elimination of theophylline in the liver, a prolonged elimination half-life (t1/2beta;), an increase in blood concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc., and should be avoided. If it cannot be avoided, theophylline blood concentration should be measured and the dose adjusted. 3. When cyclosporine is used in combination with this product, its blood concentration increases. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4. When this product is used in combination with the anticoagulant warfarin, it can enhance the latter's anticoagulant effect. When used in combination, the patient's prothrombin time should be closely monitored and the dose adjusted. 5. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, it may cause toxicity due to the increased blood concentration of this product. 6. This product interferes with the metabolism of caffeine, resulting in reduced caffeine elimination, prolonged blood elimination half-life (t1/2beta;), and may produce central nervous system toxicity. When used in combination, the patient's blood caffeine concentration should be closely monitored and the dose adjusted. 7. Antacids containing aluminum and magnesium can reduce the oral absorption of this product and should not be used in combination. 8. Avoid using it in combination with non-steroidal anti-inflammatory drugs.

Keep away from light, sealed and stored in a dry place.

0.1g (calculated as C17H18FN3O3S)

36 months.

Hubei Sihuan Pharmaceutical Co., Ltd.

• Founded in:

  2002-09-02

• Address:

  Room C6321, Building C6, No. 666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan City, Hubei Province

• Tax NO.:

  914200007417627664

• Registered Funds:

  45 million yuan

• Website:

  Log in to view

• Email:

  Log in to view